Surgery of Colorectal, Affiliated Hospital of Guizhou Medical University, Guiyang City, 550004, Guizhou, China.
Department of Imaging, Affiliated Hospital of Guizhou Medical University, Guiyang City, 550004, Guizhou, China.
Cell Biol Toxicol. 2020 Aug;36(4):333-347. doi: 10.1007/s10565-019-09506-3. Epub 2020 Jan 4.
LncRNAs (long noncoding RNAs) have been reported to critically regulate colorectal cancer (CRC). We prospectively investigated effects and mechanisms of lncRNA LINC00858 on regulation of CRC progression.
Expression of LINC00858 and its target were analyzed by quantitative real-time polymerase chain reaction and in situ hybridization. MTT and bromodeoxyuridine/5-bromo-2'-deoxyuridine (BrdU) staining to assess cell proliferation ability. Flow cytometry, wound healing, and transwell assays were conducted to evaluate cell apoptosis, migration, and invasion, respectively. Interaction between LINC00858 and its target was confirmed by luciferase activity assay and RNA immunoprecipitation. Subcutaneous xenotransplanted tumor model was established and employed to detect tumorigenic functions of LINC00858, and further evaluated by qRT-PCR, western blot, immunohistochemistry, and hematoxylin and eosin staining.
With a predicted poor prognosis, LINC00858 was upregulated in CRC patients. LINC00858 knockdown suppressed cell proliferation, invasion, and migration abilities, meanwhile induced cell apoptosis. Moreover, LINC00858 could target and inhibit the miR-4766-5p expression, thus promoting CRC progression. miR-4766-5p further suppressed serine/threonine kinase PAK2. Interestingly, interference of LINC00858 suppressed tumorigenic ability of CRC in vivo by downregulating PAK2.
LINC00858 promoted CRC progression by sponging miR-4766 to upregulate PAK2, shedding lights on LINC00858 as a potential therapeutic target candidate in CRC treatment from bench to clinic.
长链非编码 RNA(lncRNA)已被报道在结直肠癌(CRC)中起关键调节作用。我们前瞻性研究了 lncRNA LINC00858 对 CRC 进展的调节作用及其机制。
采用实时定量聚合酶链反应和原位杂交分析 LINC00858 及其靶基因的表达。MTT 和溴脱氧尿苷/5-溴-2'-脱氧尿苷(BrdU)染色评估细胞增殖能力。流式细胞术、划痕愈合和 Transwell 分析分别用于评估细胞凋亡、迁移和侵袭。通过荧光素酶活性测定和 RNA 免疫沉淀证实 LINC00858 与其靶基因的相互作用。建立皮下移植瘤模型,检测 LINC00858 的致瘤功能,并进一步通过 qRT-PCR、western blot、免疫组化和苏木精和伊红染色进行评估。
LINC00858 在 CRC 患者中呈上调表达,且与不良预后相关。LINC00858 敲低抑制细胞增殖、侵袭和迁移能力,同时诱导细胞凋亡。此外,LINC00858 可靶向并抑制 miR-4766-5p 的表达,从而促进 CRC 的进展。miR-4766-5p 进一步抑制丝氨酸/苏氨酸激酶 PAK2。有趣的是,LINC00858 的干扰通过下调 PAK2 抑制了 CRC 在体内的致瘤能力。
LINC00858 通过海绵吸附 miR-4766 而上调 PAK2 促进 CRC 进展,为 LINC00858 作为 CRC 治疗的潜在治疗靶点从实验室走向临床提供了依据。